By FDC-Windhover’s Biopharma Team
Imagine if pharmaceutical company executives "acted as if their business models had a patent expiry," mused McKinsey & Co. director...
PSA: What We Have Here Is A Failure to Innovate
Discussion at FDC/Windhover's annual Pharmaceutical Strategic Alliances gathering in New York reflected the urgent need for the industry to adopt new models in order to spur innovation--in R&D, finance, business development, and commercial operations.
More from Business Strategy
More from In Vivo
• By
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
• By
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
• By
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.